A phase II, open-label, uncontrolled, single center study to evaluate safety and immunogenicity of a commercially available surface antigen, inactivated influenza vaccine, formulation 2006-2007, when administered to non-elderly adult and elderly subjects
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 19 Apr 2017 Status changed from suspended to withdrawn prior to enrolment.
- 07 Oct 2006 New trial record.